Nuvalent filed a new drug application for an experimental non-small cell lung cancer treatment with the Food and Drug Administration.

NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass., Nov. 19, 2025 ...

Amgen's Imdelltra received full approval from the Food and Drug Administration for use in patients with lung cancer. The biotechnology company said Wednesday Imdelltra received approval for adult ...

The FDA announced accelerated approval of sevabertinib (Hyrnuo) for HER2-positive non-small cell lung cancer (NSCLC).

Just a few months after Boehringer Ingelheim broke into the oncology space with the first drug that can target a rare tumor ...

New Clinical Trial Site Added for Clinical Studies of Reqorsa® Gene Therapy to Treat Lung Cancer Acclaim-1 and Acclaim-3 ...

Tumor infiltrating lymphocyte (TIL) therapy uses immune cells harvested directly from a patient’s tumor.

Nearly 8% of Ohioans live with chronic obstructive pulmonary disease (COPD), a long-term, progressive lung disease that causes difficulty breathing. In fact, Ohio is among the states in the country ...

A year after she quit smoking, Kim Swart thought the half-million cigarettes she smoked between high school and retirement ...

New artificial intelligence technology is helping diagnose the U.S.’s most deadly cancer sooner, greatly improving the ...

Living with lung cancer often means spending more time in waiting rooms than in the moments that matter. But that could ...

A major breakthrough in cancer research has shown that using CRISPR gene editing technology to turn off a specific gene can help fight chemotherapy resistance in lung cancer. This discovery could open ...